Top in endocrinology: Plant-based Portfolio diet; osteoporosis remains undiagnosed

Recent findings from the Women’s Health Initiative revealed that greater adherence to a plant-based Portfolio diet was associated with a lower risk for incident type 2 diabetes.

Study coauthor Andrea Glenn, PhD, RD, highlighted two main takeaways from the study.

“The first is that we saw all three dietary patterns (Portfolio, Dietary Approaches to Stop Hypertension [DASH] and Mediterranean) we assessed were similarly associated with a reduced risk of developing type 2 diabetes, highlighting that there are several combinations of plant predominant diets that may be beneficial for diabetes prevention,” she told Healio. “The second would be that we saw a linear dose-response with adherence to the Portfolio diet and type 2 diabetes risk, therefore emphasizing that adopting one or more of its components is better than none for diabetes prevention.”

It was the top story in endocrinology last week.

In another top story, experts discussed how osteoporosis remains undiagnosed and untreated, despite new advancements in fracture risk assessments and treatments.

Read these and more top stories in endocrinology below:

Greater adherence to plant-based Portfolio diet cuts risk for developing type 2 diabetes

Women who adhered more to a plant-based Portfolio diet lowered their risk for developing type 2 diabetes, according to findings from the Women’s Health Initiative published in Diabetes Care. Read more.

Despite effective new therapies, osteoporosis remains undiagnosed, untreated

During the past 20 years, Endocrine Today has covered the latest advancements surrounding osteoporosis care. For its 20th year, the publication is taking a look back. Read more.

Diabetes treatment as effective as gastric bypass in diabetic kidney disease

Best diabetes medical treatment was just as effective in albuminuria remission as Roux-en-Y gastric bypass for adults with diabetic kidney disease and obesity, according to study results published in eClinical Medicine. Read more.

Use of CGM metrics more common in diabetes care, but still limited

With uptake of diabetes devices continuing to expand, more providers are shifting away from looking solely at HbA1c and toward analyzing continuous glucose monitoring data. Read more.

Should time in range replace HbA1c as the primary outcome metric for diabetes?

In this point-counter, experts debate whether time in range should replace HbA1c as the primary outcome metric for diabetes. Read more.